US OptionsDetailed Quotes
VIR240517C10000
- 0.40
- 0.000.00%
15min DelayTrading May 17 12:12 ET
0.00High0.00Low
0.00Open0.40Pre Close0 Volume228 Open Interest10.00Strike Price0.00Turnover1639.03%IV7.99%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier-2DDays to Expiry0.40Time Value100Contract SizeAmericanOptions Type0.4448Delta0.3048Gamma24.08Leverage Ratio-10.8874Theta0.0000Rho10.71Eff Leverage0.0003Vega
Vir Biotechnology Stock Discussion
Sign in to post a comment
$Vir Biotechnology(VIR.US$ They need better cost control and accounting practice to boost share price to a reasonable level (say 20). Section is bad because of Biden, but literally science is priced at 0 for VIR. Active investor should interfere. I’ll vote all Against in proxy, as I am not happy at all.
1
$Vir Biotechnology(VIR.US$ small scale experiments are good.
no idea why they issue cost guidance (huge) without revenue guidance. Stupid.
I don’t like new management goes back to clinical stage biotech. They hire too many people and relocate position to high salary area. AI expert in San Francisco, come on… If not sotrovimab and help of GSK made huge money, this company would have doomed.(if not stopped by Biden, would have been 40 dollar per share). I’ll start...
no idea why they issue cost guidance (huge) without revenue guidance. Stupid.
I don’t like new management goes back to clinical stage biotech. They hire too many people and relocate position to high salary area. AI expert in San Francisco, come on… If not sotrovimab and help of GSK made huge money, this company would have doomed.(if not stopped by Biden, would have been 40 dollar per share). I’ll start...
Morning Movers
Gapping up
$ZoomInfo(ZI.US$ The software stock popped 5.5% after Bank of America analyst Koji Ikeda upgraded it to buy from neutral. “We believe it is a classic self-help story that is set to outperform,” the analyst wrote, underscoring the company’s revenue growth reacceleration and new AI products as potential catalysts.
$Boeing(BA.US$ stock rose 0.9% after Ryanair, Europe's largest airline by passenger number...
Gapping up
$ZoomInfo(ZI.US$ The software stock popped 5.5% after Bank of America analyst Koji Ikeda upgraded it to buy from neutral. “We believe it is a classic self-help story that is set to outperform,” the analyst wrote, underscoring the company’s revenue growth reacceleration and new AI products as potential catalysts.
$Boeing(BA.US$ stock rose 0.9% after Ryanair, Europe's largest airline by passenger number...
20
$Cellectar BioSciences(CLRB.US$ Phase 2
$Regenxbio(RGNX.US$ Phase 2
$Leap Therapeutics(LPTX.US$ Phase 2
$4D Molecular Therapeutics(FDMT.US$ Phase 2
$Adverum Biotechnologies(ADVM.US$ Phase 2
$Denali Therapeutics(DNLI.US$ Phase 2
$EyePoint Pharmaceuticals(EYPT.US$ Phase 2
$Xencor(XNCR.US$ Phase 2
$Harmony Biosciences(HRMY.US$ Phase 2
$Alnylam Pharmaceuticals(ALNY.US$ Phase 2
$Disc Medicine(IRON.US$ Phase 2
$Atea Pharmaceuticals(AVIR.US$ Phase 2
$Allakos(ALLK.US$ Phase 2...
$Regenxbio(RGNX.US$ Phase 2
$Leap Therapeutics(LPTX.US$ Phase 2
$4D Molecular Therapeutics(FDMT.US$ Phase 2
$Adverum Biotechnologies(ADVM.US$ Phase 2
$Denali Therapeutics(DNLI.US$ Phase 2
$EyePoint Pharmaceuticals(EYPT.US$ Phase 2
$Xencor(XNCR.US$ Phase 2
$Harmony Biosciences(HRMY.US$ Phase 2
$Alnylam Pharmaceuticals(ALNY.US$ Phase 2
$Disc Medicine(IRON.US$ Phase 2
$Atea Pharmaceuticals(AVIR.US$ Phase 2
$Allakos(ALLK.US$ Phase 2...
36
6
The multiple insider sales in Vir Biotechnology and zero buying activity in the last year may be a concern for potential investors. However, a fair level of insider ownership suggests a reasonable alignment of interests with shareholders.
Adobe's stock fall and FTC probe may hit future results. Pfizer's reduced earnings projection could reshape investor outlook. Vir Biotechnology's austerity measures aim at fiscal stability. Nordson's weak Q1 forecast may impact near-term stocks.
$Vir Biotechnology(VIR.US$ too late to take position moved so fast
$Vir Biotechnology(VIR.US$ so stupid action. Already bought too heavy position. can only average down to 25.5.
I have confidence this is a 20 to 30 dollar stock at least.
I have confidence this is a 20 to 30 dollar stock at least.
1
$Vir Biotechnology(VIR.US$ how long these company product will get govt blessing? if ages, good to still hold or still Best time to buy more?
1
$Vir Biotechnology(VIR.US$ Just bought more. and wait for further dump to buy. Seriously, wall street are upset to Vir’s attitude, not science not finance.
This stupid trial is paid by GSK, HHS, BARDA. Let me make it frank, antibody to virus is proved to be low effectiveness and expensive, you have seen that in Covid. Regeneron faced the same issue for many years, unless trial design is tricky. There is an example antibody works as miracle cure. Regn Cov gives 1200mg antibo...
This stupid trial is paid by GSK, HHS, BARDA. Let me make it frank, antibody to virus is proved to be low effectiveness and expensive, you have seen that in Covid. Regeneron faced the same issue for many years, unless trial design is tricky. There is an example antibody works as miracle cure. Regn Cov gives 1200mg antibo...
4
No comment yet
QianmengYuOP : not bad at GSK still sells somewhat and huge interest earnings. Regardless, free science
. I bought more near support 7.8 (need to fight together with other bulls) will buy more if going down to support.